Liver tumor organoid and their preparation method

By isolating fibroblasts from normal liver tissue and co-culturing with liver cancer organoids, the method addresses purity and growth rate issues, resulting in high-quality liver cancer organoids for enhanced drug development and research.

KR103047658B1Active Publication Date: 2026-11-11CHUNGNAM NAT UNIV HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020230142821
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-10-24
Publication Date
2026-11-11
Estimated Expiration
2043-10-24

AI Technical Summary

Technical Problem

Existing methods for producing liver cancer organoids face challenges in achieving high purity and growth rate due to contamination from normal epithelial tissue and lack of biomimetic environments, leading to inefficiencies in drug development and research.

Method used

A method involving the isolation of fibroblasts from normal human liver tissue and performing non-physical co-culture with liver cancer-derived organoids to enhance growth rate and purity.

Benefits of technology

The method produces liver cancer organoids of superior quality and quantity, improving growth rates and enabling more accurate drug metabolism and screening results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112023116691474-PAT00004_ABST
    Figure 112023116691474-PAT00004_ABST
Patent Text Reader

Abstract

The present invention relates to a liver cancer organoid and a method for manufacturing the same.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a method for manufacturing liver cancer organoids. Background Technology

[0003] Organoids are organ-like structures that replicate characteristic body organs in vitro and serve as models for research or treatment. They are currently utilized in various fields such as new drug development, cancer research, personalized medicine, and regenerative therapy. Organoid-based platforms can replicate the physiological activity of the human body and overcome the limitations of existing 2D cell lines by utilizing them as platforms for personalized and precision medicine. This includes disease modeling based on the patient's genetic information and drug screening through repeated experiments, by constructing organoids from the patient's tissues.

[0004] Among human organs, liver organoids have high utility in areas such as screening for new drug development based on liver disease modeling and liver tumor research. In particular, liver tumor organoids are expected to be useful in the production of organoids for personalized medicine regarding liver cancer, rapid cancer evaluation through comparison of cancer cells with normal cells from the same patient, and the development of immunotherapies.

[0005] As such, organoids derived from a patient's cancer tissue can be utilized as preclinical test models to ensure the clinical potential of candidate drugs in the development of anticancer drugs. Additionally, they are easy to culture and proliferate, allow for reproducible repeated testing of drugs at various concentrations, and enable personalized treatment through patient-specific organoid biobanks.

[0006] However, since the use of tumor tissue-derived organoids is accompanied by contamination with organoids from normal epithelial tissue, it is difficult to guarantee the substantial and accurate in vivo reflection of drug metabolic responses specific to tumor tissue; therefore, it is necessary to produce tumor tissue-derived organoids of superior quality and quantity for various studies utilizing them, including drug metabolic evaluation.

[0007] In the application of organoid technology for cancer research, the lack of biomimetic environments—such as stroma, blood vessels, and various immune cells—results in significant time and resource consumption for organoid generation and culture compared to cancer cell lines. Furthermore, organoids derived from advanced cancer tissues grow more slowly than those derived from normal epithelial tissues. In other words, contaminated normal epithelial organoids can grow excessively faster than cancer organoids, and this outcome poses a limiting factor to the utilization of pure cancer organoids.

[0008] To date, efforts to complement these aspects have focused on fabricating stem cell-based organoids, controlling the stem cell microenvironment, optimizing culture media and methods, and optimizing signaling molecules, but barriers still exist.

[0009] The present invention aimed to produce liver cancer-derived organoids of superior quality and quantity and establish a platform, thereby expecting more accurate and reliable results in various studies utilizing organoids, including drug development. Prior art literature

[0011] Korean Published Patent No. 2021-0065970, Korean Registered Patent No. 2360023 The problem to be solved

[0012] The present invention was devised to solve the above-mentioned problems and aims to provide a liver cancer organoid of superior quality and quantity, capable of improving growth rate and purity by isolating fibroblasts from normal human liver tissue and performing non-physical co-culture with a liver cancer-derived organoid, as well as a method for manufacturing the same. means of solving the problem

[0014] The present invention provides a method for producing a liver cancer organoid with an improved growth rate, comprising: 1) a step of producing a liver cancer organoid from isolated liver cancer tissue; 2) a step of isolating fibroblasts from isolated liver tissue; and 3) a step of inversely co-culturing the liver cancer organoid and fibroblasts.

[0015] In this specification, the term "organoid" refers to a three-dimensional cell aggregate formed through self-renewal and self-organization from adult stem cells (ASCs), embryonic stem cells, and induced pluripotent stem cells (iPSCs). An organoid is a small, simplified, in vitro three-dimensional organ that mimics the anatomical structure of actual tissues. By constructing an organoid from a patient's tissue, it enables disease modeling based on the patient's genetic information and drug screening through repeated testing.

[0016] The step of preparing the above liver cancer organoid may include: 1-1) cutting the liver cancer tissue into 2 to 3 mm pieces in a buffer; 1-2) reacting with a collagenase in a serum-free culture medium; and 1-3) culturing in a medium dedicated to organoid production.

[0017] In this specification, the term "medium" refers to a medium capable of supporting the proliferation, survival, and differentiation of liver organoids or fibroblasts in vitro, and includes all conventional media suitable for the culture and differentiation of liver organoids or fibroblasts used in the field. Depending on the type of cell, the type of medium and culture conditions may be appropriately selected.

[0018] Specifically, the medium may generally include a cell culture minimum medium (CCMM) containing a carbon source, a nitrogen source, and trace element components. Examples of the cell culture minimum medium include, but are not limited to, DMEM (Dulbecco's Modified Eagle's Medium), F-10, F-12, DMEM / F12, Advanced DMEM / F12, α-MEM (α-Minimal Essential Medium), IMDM (Iscove's Modified Dulbecco's Medium), BME (Basal Medium Eagle), RPMI1640, etc.

[0019] The above medium may contain antibiotics such as penicillin, streptomycin, gentamicin, or a mixture of two or more of these.

[0020] As a preferred embodiment of the present invention, a medium dedicated to organoid generation may comprise, but is not limited to, N2, B27, N-acetylcysteine, Leu15-Gastrin, nicotinamide, A83-01, forskolin, recombinant human epidermal growth factor (rhEGF), recombinant human fibroblast growth factor-10 (rhFGF-10), recombinant human hepatocyte growth factor (rhHGF), Y-27632, dexamethasone, and R-spondin 1.

[0021] The step of isolating the above fibroblasts may include: 2-1) cutting liver tissue into 2 to 3 mm pieces in a buffer; 2-2) reacting with a liberase enzyme in a serum-free culture medium; and 2-3) culturing in a fibroblast culture medium.

[0022] The above inverted co-culture step may include 3-1) a step of culturing fibroblasts in a lower culture vessel; and 3-2) a step of dispensing liver cancer organoids in the shape of a dome into a permeable culture vessel at the top.

[0023] In one embodiment of the present invention, the present invention provides a liver cancer organoid produced by the above-described method for producing liver cancer organoids.

[0024] In another embodiment of the present invention, the present invention provides a liver cancer treatment screening method comprising: 1) a step of culturing a liver cancer organoid according to claim 6; 2) a step of administering a candidate drug to the liver cancer organoid; and 3) a step of measuring changes in the liver cancer organoid.

[0025] In another embodiment of the present invention, the present invention provides a method for evaluating drug metabolism comprising: 1) a step of culturing a liver cancer organoid according to claim 6; 2) a step of administering a candidate drug to the liver cancer organoid; and 3) a step of evaluating the metabolism of the candidate drug. Effects of the invention

[0027] The liver cancer organoid produced by the manufacturing method according to the present invention is excellent in both quality and quantity, and thus can derive and improve accurate mechanism studies and drug metabolism results for cancer research and drug screening for anticancer drug development using organoids. Brief explanation of the drawing

[0029] FIG. 1 shows a normal tissue-derived organoid (A) and a liver cancer tissue-derived organoid (B) according to one embodiment of the present invention. Figure 2 shows fibroblasts isolated from tissue derived from a liver cancer patient according to one embodiment of the present invention. FIG. 3 shows an inverted co-culture for liver cancer tissue organoid culture according to one embodiment of the present invention. Figure 4 shows the results of comparing organoid growth rates through inverted co-culture of fibroblasts and organoids according to one embodiment of the present invention. A relates to a normal organoid, and B relates to a liver cancer organoid. *p<0.05, **p<0.01, ****p<0.0001. Specific details for implementing the invention

[0030] Preferred embodiments of the present invention will be described in detail below. In addition, many specific details, such as specific components, are illustrated in the following description; however, these are provided merely to aid in a more comprehensive understanding of the present invention, and it will be obvious to those skilled in the art that the present invention can be practiced without such specific details. Furthermore, in describing the present invention, detailed descriptions of related known functions or configurations are omitted if it is determined that such detailed descriptions may unnecessarily obscure the essence of the present invention.

[0032] Example 1. Preparation of normal and liver cancer-derived organoids from liver tissue of liver cancer patients (Fig. 1)

[0033] A. Normal and liver cancer tissues derived from liver cancer patients are finely chopped (2-3 mm) with a scalpel in phosphate-buffered saline (DPBS; Ca, Mg free). The DPBS can be changed to HBSS buffer or a culture medium dedicated to organoids.

[0034] B. Transfer the finely chopped tissue and DPBS to a 50ml tube and centrifuge (300g / 5 min).

[0035] C. Remove the supernatant DPBS and add 5-10 ml of DMEM / F12 (with 15 mM HEPES).

[0036] D. After adding 2.5 mg / ml collagenase D (Roche) and 10 mg / ml DNase I (Roche) to 10 ml DMEM / F12 (with 15 mM HEPES), the enzymatic reaction is carried out in a 37°C incubator with inversion (slow speed) (normal tissue: 1 hour / liver cancer tissue: 2 hours).

[0037] E. After the enzymatic reaction is complete, remove any undigested tissue using a 100 μm cell strainer, add DMEM / F12 (with 15 mM HEPES), and centrifuge (300 g / 5 min). If red blood cells remain in the cells after centrifugation, they can be removed using RBC Lysis Buffer (Gibco).

[0038] F. Remove the supernatant and release the cells into fresh DMEM / F12 (with 15mM HEPES), then perform cell counting.

[0039] G. 1 x 10 6 After dispensing 1 / ml of cells into a dome-shaped container in a 6-well plate with BME type 2 (R&D system), culture in medium dedicated to organoid generation. (5% CO₂ 2, 37℃)

[0040] H. Replace with a new medium after 24 hours.

[0041] I. Afterwards, observe organoid growth and replace the medium every 2-3 days. The normal liver tissue-derived organoid medium is Hepaticult. TM The organoid initiation medium (human), (Stemcell Technology, cat#100-0384) is used.

[0042] Liver cancer tissue-derived organoid media were prepared and used as shown in the composition below (Table 1).

[0044] Tumor Medium Company Final Conc. N2 gibco 1x B27 gibco 1x N-Acetylcysteine Tocris 1.25mM Leu15-Gastrin Sigma 10nM Nicotinamide Tocris 10mM A83-01 Tocris 5μM Foskolin Tokris 10μM rhEGF R&D system 50ng / ml rhFGF-10 R&D system 100ng / ml rhHGF R&D system 25ng / ml Y-27632 Tocris 10μM Dexamethasone Tocris 30μM R-spondin 1 R&D system 500ng / ml

[0046] Example 2. Isolation of fibroblasts from normal and liver cancer tissues of liver cancer patients (Fig. 2)

[0047] A. Normal and liver tissues from liver cancer patients are cut into 2-3 mm pieces in phosphate-buffered saline (DPBS; Ca, Mg free) or HBSS buffer.

[0048] B. After placing tissue and 5 ml of HBSS containing 0.25 mg / mL of Liberase TH (Roche) into a 15 ml tube, the enzymatic reaction is carried out in a rotatable 37°C incubator for 0.5 to 1 hour.

[0049] C. After adding DMEM / F12 (with 15 mM HEPES), remove undissolved tissue using a 100 μm strainer.

[0050] D. Harvest cells by centrifugation (1,300 rpm / 3 min).

[0051] E. After re-suspending cells in DMEM / F12 (with 15 mM HEPES), remove unnecessary tissue using a 70 μm strainer.

[0052] F. Harvest cells by centrifugation (1,300 rpm / 3 min).

[0053] G. After washing the cells with DPBS, harvest the cells by centrifugation (1,300 rpm / 3 min).

[0054] H. Culture in a 60mm plate with FBM™ Fibroblast Growth Basal Medium (Lonza) (5% CO₂ 2, 37℃). If red blood cells remain in the cells after centrifugation, remove the red blood cells using RBC Lysis Buffer (gibco) and culture in a 60mm plate.

[0055] I. After 24 hours, replace the culture medium and remove cells other than fibroblasts.

[0056] J. Afterwards, replace the culture medium at intervals of 2-3 days, and perform subculture once a sufficient number of cells is secured.

[0058] Example 3. Inverted co-culture of liver cancer-derived organoids and fibroblasts (Fig. 3)

[0059] A. Fibroblasts (1 5 Cultivate / well)

[0060] B. After 24 hours, place Falcon® Permeable Support for 6-well Plate with 0.4 μm Transparent PET Membrane (cell culture inserts, [CORNING]) on top of the cultured fibroblasts, and place 1 x 10⁶ on the cell culture inserts. 5 / ml organoids are dispensed in the shape of a dome.

[0061] C. Maintain culture under conditions of 5% CO2, 37℃, and replace the culture medium every 2-3 days.

[0063] Example 4. Comparison of culture rates (Fig. 4)

[0064] A. Perform inverted co-culture of organoids and fibroblasts, and after 2 and 10 days, observe five randomly selected organoids each from normal tissue-derived organoids and cancer tissue-derived organoids through a microscope and take photographs at 100x magnification.

[0065] B. Use the Image J analysis program to calculate the radius value of each organoid and substitute it into the formula for calculating the area of ​​a circle (3.14 x radius x radius).

[0066] C. Calculate the final value for each sample and the average value.

[0067] D. All data were expressed as mean ± standard error, and parametric statistical tests (Student t-test) were performed using Graph Pad Prism (Ver. 8.0).

[0068] E. The p-values ​​between groups were determined on days 2 and 10 for normal tissue-derived organoids and cancer tissue-derived organoids, respectively, between the group cultured organoids alone and the group co-cultured with normal tissue-derived fibroblasts, or between the group cultured organoids alone and the group co-cultured with cancer tissue-derived fibroblasts.

[0070] Fibroblasts were isolated from normal and liver cancer tissues provided by liver cancer patients using the method of Example 2, respectively, and each fibroblast was co-cultured with normal organoids and liver cancer organoids. After 10 days of co-culture, the size of each formed organoid was measured (n=5), and the significance was confirmed.

[0071] The growth rate of both normal organoids and liver cancer organoids was enhanced when co-cultured with fibroblasts isolated from normal and liver cancer tissues, and a significant improvement in growth rate was observed when organoids were co-cultured with fibroblasts isolated from normal tissue compared to fibroblasts isolated from liver cancer tissue.

[0072] In addition, when fibroblasts isolated from normal tissue were used, the growth rate of normal organoids was improved by about 1.5 times, but when co-cultured with liver cancer organoids, the growth rate was improved by about 3 times, confirming that the condition capable of inducing the highest growth rate among the experimental groups of the present invention is co-culture of normal tissue-derived fibroblasts and liver cancer tissue-derived organoids.

Claims

Claim 1 A method for producing a liver cancer organoid with improved growth rate, comprising: 1) a step of producing a liver cancer organoid from isolated liver cancer tissue; 2) a step of isolating fibroblasts from isolated normal liver tissue; and 3) a step of dispensing the liver cancer organoid in the shape of a dome into an upper permeable culture vessel and culturing the fibroblasts in a lower culture vessel to non-physical co-culture the liver cancer organoid and the fibroblasts. Claim 2 A method for preparing a liver cancer organoid according to claim 1, wherein the step of preparing the liver cancer organoid comprises: 1-1) cutting the liver cancer tissue into 2 to 3 mm pieces in a buffer solution; 1-2) reacting with a collagenase in a serum-free culture medium; and 1-3) culturing in a medium dedicated to organoid production. Claim 3 A method for preparing a liver cancer organoid according to claim 2, wherein the medium dedicated to organoid generation comprises N2, B27, N-acetylcysteine, Leu15-Gastrin, nicotinamide, A83-01, forskolin, recombinant human epidermal growth factor (rhEGF), recombinant human fibroblast growth factor-10 (rhFGF-10), recombinant human hepatocyte growth factor (rhHGF), Y-27632, dexamethasone, and R-spondin 1. Claim 4 A method for preparing a liver cancer organoid according to claim 1, wherein the step of isolating the fibroblasts comprises: 2-1) cutting liver tissue into 2 to 3 mm pieces in a buffer; 2-2) reacting with a serum-free culture medium and a liberase enzyme; and 2-3) culturing in a fibroblast culture medium. Claim 5 delete Claim 6 A liver cancer organoid manufactured by the method for manufacturing a liver cancer organoid according to any one of claims 1 to 4; characterized by having an improved growth rate compared to a normal liver tissue-derived organoid. Claim 7 A method for screening liver cancer therapeutic agents comprising: 1) a step of culturing the liver cancer organoid according to claim 6; 2) a step of administering a candidate drug to the liver cancer organoid; and 3) a step of measuring changes in the liver cancer organoid. Claim 8 A method for evaluating drug metabolism comprising: 1) a step of culturing a liver cancer organoid according to claim 6; 2) a step of administering a candidate drug to the liver cancer organoid; and 3) a step of evaluating the metabolism of the candidate drug.